ClinicalTrials.gg
CompletedNCT01095666Updated Sep 11, 2017Results posted

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

A Phase 3 interventional study of Dapagliflozin and Dapagliflozin in Type 2 Diabetes, sponsored by AstraZeneca. Completed at 33 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-11.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,484
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
9th of 287
1,484 · median 100
Started
2010
with 19 others
Phase 3
72 of 293
1 open now
Registered
109th of 293
by date
Lead sponsor
19 of 293
AstraZeneca

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment of the 287 interventional ones that give a count, is one of 20 that started in 2010, is one of 72 in phase 3, and was the 109th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in Asian patients with Type 2 Diabetes who are not well controlled on metformin alone. The safety of this treatment will also be studied.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females, 18 to 77 years old, with type 2 diabetes and with inadequate glycemic control
  • Drug naive or treated with anti-diabetic medication for \< 24 weeks
  • C-peptide ≥ 1.0 ng/mL
  • ≤ 45.0 kg/m²

Exclusion criteria

Exclusion Criteria:

  • and/or ALT > 3 times
  • Serum total > 2 mg/dL
  • Serum creatinine ≥ 1.50 mg/dL for men or ≥ 1.40 mg/dL for women
  • Creatine kinase ≥ 3 times ULN
  • Symptoms of severely uncontrolled diabetes
  • Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,484 participants (actual)

Study arms

  • Experimental
    Group 1

    Drug: Dapagliflozin · Drug: Metformin · Drug: Dapagliflozin Placebo · Drug: Pioglitazone

  • Experimental
    Group 2

    Drug: Dapagliflozin · Drug: Metformin · Drug: Dapagliflozin Placebo · Drug: Pioglitazone

  • Experimental
    Group 3

    Drug: Metformin · Drug: Dapagliflozin Placebo · Drug: Pioglitazone

Interventions

  • Tablets, Oral, 5 mg, Once daily, 24 weeks

    Also known as: BMS-512148

  • Tablets, Oral, 10 mg, Once daily, 24 weeks

    Also known as: BMS-512148

  • Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks

    Also known as: Glucophage®

  • DrugDapagliflozin Placebo

    Tablets, Oral, 0 mg, Once daily, 24 weeks

  • Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])

    HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the double-blind period.

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])

    Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Fasting plasma glucose was measured as milligrams per deciliter(mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 4, 8, 12, 16, 20, and 24 in the double-blind period.

    Time frame: From Baseline to Week 24

  2. Adjusted Mean Change From Baseline in 2-hour Post Meal Glucose (PMG) (mg/dL) at Week 24 (Last Observation Carried Forward [LOCF])

    Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Post Meal Glucose was measured as milligrams per deciliter(mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. PMG measurements were obtained on Day 1 and week 24 in the double-blind period.

    Time frame: From Baseline to Week 24

  3. Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])

    Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 4, 8, 12, 16, 20, and 24 of the double-blind period.

    Time frame: From Baseline to Week 24

  4. Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])

    Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Therapeutic glycemic response is defined as HbA1c \<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin. Percentage of participants were estimated by modified logistic regression model, adjusted for baseline HbA1c.

    Time frame: From Baseline to Week 24

07

Results

Posted Sep 11, 2017

Participant flow

Of 1484 patients enrolled, 554 completed a qualification period. Of these 554 patients, 444 were randomized and received treatment. Of these 444 participants, 409 completed the double-blind treatment period

Participant flow — Overall Study
MilestonePlacebo + MetforminDapagliflozin 5 mg + MetforminDapagliflozin 10 mg + Metformin
Started145147152
Completed128136145
Not completed17117
Withdrew: Lack of efficacy001
Withdrew: Adverse event213
Withdrew: Lost to follow-up220
Withdrew: Withdrawal by subject661
Withdrew: Non-compliance, not met criteria etc.722

Outcome measures

PrimaryAdjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])

HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the double-blind period.

Time frame:
From Baseline to Week 24
Reported as:
Mean · % of hemoglobin
Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])
% of hemoglobinPlacebo + MetforminDapagliflozin 5 mg + MetforminDapagliflozin 10 mg + Metformin
Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])-0.23 ± 0.0622-0.82 ± 0.0607-0.85 ± 0.0601
Statistical analysis
  • Placebo + Metformin vs Dapagliflozin 5 mg + Metformin · ANCOVA · p = <0.0001 (Primary endpoints were tested at alpha=0.027 applying Dunnett's adjustment.) · Mean difference (final values): -0.59 · 95% CI -0.76 to -0.42
  • Placebo + Metformin vs Dapagliflozin 10 mg + Metformin · ANCOVA · p = <0.0001 (Primary endpoints were tested at alpha=0.027 applying Dunnett's adjustment.) · Mean difference (final values): -0.62 · 95% CI -0.79 to -0.45
SecondaryAdjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])

Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Fasting plasma glucose was measured as milligrams per deciliter(mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 4, 8, 12, 16, 20, and 24 in the double-blind period.

Time frame:
From Baseline to Week 24
Reported as:
Mean · mg/dL
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])
mg/dLPlacebo + MetforminDapagliflozin 5 mg + MetforminDapagliflozin 10 mg + Metformin
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])0.5 ± 2.357-21.6 ± 2.308-26.6 ± 2.269
Statistical analysis
  • Placebo + Metformin vs Dapagliflozin 5 mg + Metformin · ANCOVA · p = <0.0001 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05.) · Mean difference (final values): -22.1 · 95% CI -28.6 to -15.6
  • Placebo + Metformin vs Dapagliflozin 10 mg + Metformin · ANCOVA · p = <0.0001 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05.) · Mean difference (final values): -27.1 · 95% CI -33.5 to -20.7
SecondaryAdjusted Mean Change From Baseline in 2-hour Post Meal Glucose (PMG) (mg/dL) at Week 24 (Last Observation Carried Forward [LOCF])

Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Post Meal Glucose was measured as milligrams per deciliter(mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. PMG measurements were obtained on Day 1 and week 24 in the double-blind period.

Time frame:
From Baseline to Week 24
Reported as:
Mean · mg/dL
Adjusted Mean Change From Baseline in 2-hour Post Meal Glucose (PMG) (mg/dL) at Week 24 (Last Observation Carried Forward [LOCF])
mg/dLPlacebo + MetforminDapagliflozin 5 mg + MetforminDapagliflozin 10 mg + Metformin
Adjusted Mean Change From Baseline in 2-hour Post Meal Glucose (PMG) (mg/dL) at Week 24 (Last Observation Carried Forward [LOCF])-15.5 ± 4.1548-57.8 ± 4.1547-64.6 ± 4.0357
Statistical analysis
  • Placebo + Metformin vs Dapagliflozin 5 mg + Metformin · ANCOVA · p = <0.0001 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05.) · Mean difference (final values): -42.3 · 95% CI -53.84 to -30.73
  • Placebo + Metformin vs Dapagliflozin 10 mg + Metformin · ANCOVA · p = <0.0001 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05.) · Mean difference (final values): -49.1 · 95% CI -60.53 to -37.74
SecondaryAdjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])

Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 4, 8, 12, 16, 20, and 24 of the double-blind period.

Time frame:
From Baseline to Week 24
Reported as:
Mean · kg
Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])
kgPlacebo + MetforminDapagliflozin 5 mg + MetforminDapagliflozin 10 mg + Metformin
Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])-0.74 ± 0.1975-1.84 ± 0.1935-2.56 ± 0.1909
Statistical analysis
  • Placebo + Metformin vs Dapagliflozin 5 mg + Metformin · ANCOVA · p = <0.0001 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05.) · Mean difference (final values): -1.10 · 95% CI -1.65 to -0.56
  • Placebo + Metformin vs Dapagliflozin 10 mg + Metformin · ANCOVA · p = <0.0001 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05.) · Mean difference (final values): -1.82 · 95% CI -2.36 to -1.28
SecondaryParticipants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])

Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Therapeutic glycemic response is defined as HbA1c \<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin. Percentage of participants were estimated by modified logistic regression model, adjusted for baseline HbA1c.

Time frame:
From Baseline to Week 24
Reported as:
Number · Percentage of Participants
Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])
Percentage of ParticipantsPlacebo + MetforminDapagliflozin 5 mg + MetforminDapagliflozin 10 mg + Metformin
Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])17.5 ± 3.13632.9 ± 3.66733.0 ± 3.528
Statistical analysis
  • Placebo + Metformin vs Dapagliflozin 5 mg + Metformin · Modified logistic regression · p = 0.0010 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05.) · Difference in percentage: 15.4 · 95% CI 6.2 to 24.7Modified logistic regression model, adjusted for baseline HbA1c
  • Placebo + Metformin vs Dapagliflozin 10 mg + Metformin · Modified logistic regression · p = 0.0007 (Secondary endpoints were tested following a sequential testing procedure at alpha=0.05.) · Difference in percentage: 15.5 · 95% CI 6.5 to 24.5Modified logistic regression model, adjusted for baseline HbA1c

Adverse events

Collected over Onset on or after the first date of double-blind treatment and on or prior to the last day of double-blind treatment 24 weeks plus 4 days for non-serious adverse event; plus 30 days for serious adverse event.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Metformin—6/145 (4.1%)34/145 (23.4%)
Dapagliflozin 5 mg + Metformin—3/147 (2%)43/147 (29.3%)
Dapagliflozin 10 mg + Metformin—3/152 (2%)42/152 (27.6%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPlacebo + MetforminDapagliflozin 5 mg + MetforminDapagliflozin 10 mg + Metformin
JOINT INJURYInjury, poisoning and procedural complications1/1450/1470/152
SQUAMOUS CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1450/1470/152
ANGINA UNSTABLECardiac disorders1/1450/1470/152
MYOCARDIAL BRIDGINGCongenital, familial and genetic disorders1/1450/1470/152
ABDOMINAL HERNIAGastrointestinal disorders1/1450/1470/152
PNEUMONIAInfections and infestations1/1450/1470/152
BENIGN PROSTATIC HYPERPLASIAReproductive system and breast disorders1/1450/1470/152
ASTHMARespiratory, thoracic and mediastinal disorders1/1450/1470/152
INFLAMMATORY PSEUDOTUMOURNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1451/1470/152
LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1451/1470/152
Most frequent other events
Most frequent other events
EventPlacebo + MetforminDapagliflozin 5 mg + MetforminDapagliflozin 10 mg + Metformin
HYPERLIPIDAEMIAMetabolism and nutrition disorders16/14518/14718/152
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations3/14514/1476/152
URINARY TRACT INFECTIONInfections and infestations7/1456/14710/152
NASOPHARYNGITISInfections and infestations5/1459/1477/152
HYPERURICAEMIAMetabolism and nutrition disorders8/1456/1473/152

Baseline characteristics

All randomized participants who received at least 1 dose of study medication

Age, Continuous
Age, Continuous(Years)Placebo + MetforminDapagliflozin 5 mg + MetforminDapagliflozin 10 mg + MetforminTotal
Mean53.5 ± 9.2053.1 ± 9.0954.6 ± 9.5453.8 ± 9.29
Age, Customized
Age, Customized(Participants)Placebo + MetforminDapagliflozin 5 mg + MetforminDapagliflozin 10 mg + MetforminTotal
Yonger than 65 years129132126387
65 to younger than 75 years14132552
75 years and older2215
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Placebo + MetforminDapagliflozin 5 mg + MetforminDapagliflozin 10 mg + MetforminTotal
Male866788241
Female598064203
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo + MetforminDapagliflozin 5 mg + MetforminDapagliflozin 10 mg + MetforminTotal
Asian Indian10111334
Chinese126127129382
Korean991028
08

Study locations

33 sites
  • Local Institution
    Hefei, Anhui 230022, China
  • Local Institution
    Beijing, Beijing 100001, China
  • Local Institution
    Beijing, Beijing 100029, China
  • Local Institution
    Beijing, Beijing 100044, China
  • Local Institution
    Beijing, Beijing 100700, China
  • Local Institution
    Beijing, Beijing 100730, China
  • Local Institution
    Chongqing, Chongqing 400016, China
  • Local Institution
    Guangzhou, Guangdong 510120, China
  • Local Institution
    Haerbin, Heilongjiang 150001, China
  • Local Institution
    Changsha, Hunan 410000, China
  • Local Institution
    Changsha, Hunan 410008, China
  • Local Institution
    Nanjing, Jiangsu 210006, China
  • Local Institution
    Nanjing, Jiangsu 210008, China
  • Local Institution
    Wuxi, Jiangsu 214023, China
  • Local Institution
    Changchun, Jilin 130041, China
  • Local Institution
    Shenyang, Liaoning 110003, China
  • Local Institution
    Shanghai, Shanghai 200003, China
  • Local Institution
    Shanghai, Shanghai 200040, China
  • Local Institution
    Shanghai, Shanghai 200065, China
  • Local Institution
    Chengdu, Sichuan 610070, China
  • Local Institution
    Chongqing, Sichuan 400010, China
  • Local Institution
    Tianjin, Tianjin 300211, China
  • Local Institution
    Hangzhou, Zhejiang 310009, China
  • Local Institution
    Xi'An, 710032, China
  • Local Institution
    Bangalore, Karnataka 560 043, India
  • Local Institution
    Indore, Madhya Pradesh 452010, India
  • Local Institution
    Bangalore, 560092, India
  • Local Institution
    Jaipur, 302023, India
  • Local Institution
    Vellore, Tamilnadu, 632004, India
  • Local Institution
    Seoul, Nowon-Gu 139-711, Korea, Republic of
  • Local Institution
    Busan, 614-735, Korea, Republic of
  • Local Institution
    Seoul, 120-752, Korea, Republic of
  • Local Institution
    Seoul, 137-040, Korea, Republic of
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2017, 4 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2010
First posted
Mar 30, 2010
Start
Jun 2010
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Sep 11, 2017
Last update
Sep 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01095666
Lead sponsor
AstraZeneca
Collaborators
AstraZeneca, Bristol-Myers Squibb
Responsible party
Sponsor
First posted
Mar 30, 2010
Start date
Jun 2010
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Sep 11, 2017
Last update
Sep 11, 2017

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion